Alpha Tau Medical (NASDAQ:DRTS) presented early clinical results from the first three patients treated in its REGAIN study of Alpha DaRT for recurrent glioblastoma, with company executives and ...
An archived webcast will be available following the event.
Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all ...
Alpha Tau said it will discuss interim data on Monday from the first three patients treated in its U.S. Regain study evaluating Alpha DaRT in patients with recurrent Glioblastoma. ・Alpha DaRT uses ...
First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA ...
Dark matter particles could be mediators of the interaction between electrons and atomic nuclei, as shown by a study ...
A spike in atmospheric radiation from a major solar flare in November 2025 was picked up by a global network of soil moisture sensors. Now, a new ...
Matter behaves strangely under extreme conditions, and often, remnants of these behaviors are left behind even when ...
Hosted on MSN
Alpha Tau to unveil early US brain cancer trial data
Key trial update: Alpha Tau will present interim data from its U.S. Regain study on recurrent glioblastoma, focusing on safety and feasibility. Novel treatment approach: Alpha DaRT implants radium-224 ...
A link between particle physics and gravity equations, called the double copy, applies to Hawking radiation, creating a new ...
TerraPower Isotopes announced it has broken ground broke in the Bellwether District of Philadelphia on what it claims will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results